Feb 5 (Reuters) - EyePoint Pharmaceuticals Inc EYPT.O:
EYEPOINT ANNOUNCES POSITIVE SIX-MONTH RESULTS FOR THE PHASE 2 VERONA CLINICAL TRIAL OF DURAVYU™ FOR DIABETIC MACULAR EDEMA MEETING PRIMARY AND SECONDARY ENDPOINTS
EYEPOINT PHARMACEUTICALS INC - PRIMARY ENDPOINT ACHIEVED BY BOTH DURAVYU DOSES
EYEPOINT PHARMACEUTICALS INC: PHASE 3 NON-INFERIORITY PIVOTAL PROGRAM INITIATION ANTICIPATED BY END OF 2025 -
EYEPOINT PHARMACEUTICALS INC - PHASE 3 NON-INFERIORITY PROGRAM INITIATION EXPECTED BY END OF 2025
EYEPOINT PHARMACEUTICALS INC - NO DURAVYU-RELATED OCULAR OR SYSTEMIC SAES REPORTED
Source text: ID:nGNX9wF18z
Further company coverage: EYPT.O